- Some patients may only experience mild anemia, managed by avoiding acute exposure to cold. Most patients require treatment. There are no FDA- or EMA-approved medications for CAD
- Most patients treated with immunotoxic therapy do not have a complete response. For those that do respond, the time to achieve a response can take several months and most patients relapse with no alternative treatment options
- Significant unmet need exists for an approved, safe, and fast-acting therapy that can normalize hemoglobin and remove the dependence upon transfusions
CAD is characterized by the presence of autoantibodies called cold agglutinins that bind to a specific cell surface protein on red blood cells. Cold agglutinins are potent activators of the Classical Complement Pathway, leading to deposition of C3b on red blood cells. These C3b-coated red blood cells are phagocytosed in the liver causing extravascular hemolysis, the primary driver of anemia in CAD patients.